Low Dose Naltrexone in Dermatology

Joanna Jaros, Peter Lio

Research output: Contribution to journalArticlepeer-review

Abstract

Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn’s disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Marie-Tooth, and multiple sclerosis.1-5 Recently, off label LDN has been shown to improve dermatologic conditions such as systemic sclerosis, Hailey-Hailey Disease, lichen planopilaris, and guttate psoriasis.6-9 In this article, we examine the existing evidence for use of LDN in skin disease and discuss its potential application in the treatment of atopic dermatitis (AD). J Drugs Dermatol. 2019;18(3):235-238.

Original languageEnglish (US)
Pages (from-to)235-238
Number of pages4
JournalJournal of drugs in dermatology : JDD
Volume18
Issue number3
StatePublished - Mar 1 2019

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Low Dose Naltrexone in Dermatology'. Together they form a unique fingerprint.

Cite this